Biotech Startups

Mind Emulation Foundation funds and conducts scientific research focused on advancing the technical feasibility of emulating human minds digitally via connectome mapping and digital reconstruction. The organization works toward making mind emulation technology accessible to the general public.

1 investor

Minerva Neurosciences is a clinical-stage biopharmaceutical company developing product candidates for central nervous system disorders. It focuses on designing clinical trials with endpoints tied to patient benefit.

1 investor

Guangzhou Yinming Biomedical Technology is a China-based company developing novel drugs in-house, with a pipeline spanning ophthalmic therapies, recombinant protein botulinum toxin, cancer immunotherapy, and pet immunology drugs. Its research is led by a team of scientists and its main candidates have reached the clinical stage.

1 investor

Minicircle develops non-viral plasmid gene therapy for consumer health and wellness, with its lead product aimed at supporting lean muscle, vitality, and lowering epigenetic age. The therapy is offered to individuals through health clinics in Central America.

1 investor

SCHOTT MINIFAB provides contract design, development, and manufacturing services for life science research and diagnostic consumables, including cleaned and coated substrates for in vitro diagnostics and research applications. It specializes in microarray, microfluidic, and injection molding techniques and serves product developers in the diagnostics and life science tools market, with production in the United States, Germany, and Australia.

1 investor

Miphic provides imaging-based diagnostic screening of mitochondrial function to identify drug efficacy and personalized treatment options for cancer, neurodegenerative disease, diabetes, and aging-related conditions. The platform screens up to 96 conditions simultaneously to support drug discovery, personalized medicine selection, and metabolic research.

1 investor

MiraDx develops genetic biomarker tests, such as PREVIOTOX and PROSTOX Ultra, that help physicians assess cancer patients' risk of treatment-related toxicity and response to therapies like immunotherapy and radiation. The company applies novel biomarkers, including the inherited KRAS-variant, to support more personalized cancer care decisions.

1 investor

MiraBiologics is a Japanese biopharmaceutical drug discovery company that uses its LassoGraft Technology to graft cyclic peptides onto scaffold proteins for the development of novel biologics. It pursues collaborative R&D partnerships to create innovative biopharmaceuticals.

1 investor

MFC Co., Ltd. manufactures active pharmaceutical ingredients (APIs) and key starting materials, and conducts R&D and mass production in pharmaceuticals and materials. Using high-purity crystallization technology, it develops and supplies Statin-class APIs such as TBFA and TPPBr, focusing on domestic production of imported pharmaceutical ingredients in South Korea.

1 investor

Mirai Bio develops novel vaccines and therapeutics, with work spanning process development, CMC, and manufacturing. It operates in the biotechnology and gene therapy space.

1 investor

Miramoon Pharma develops neuroprotective small molecule therapies targeting degenerative disorders including ophthalmology, skeletal and cardiac muscle diseases, and central nervous system conditions. The company was spun out from the University of the Basque Country and Biogipuzkoa Health Research Institute.

1 investor

Miraqules develops biomaterial-based wound healing products for point-of-care medical applications. The company creates affordable, fast-acting solutions including products like StopBleed and InstaBrin, targeting the global healthcare market.

1 investor

Mirata Pharmaceuticals is developing pain-relieving drugs intended to provide the analgesic benefits of opioids without their addictive properties and serious side effects. It targets patients and physicians seeking safer alternatives to prescription opioids.

1 investor

Mireca develops treatments for rare, inherited retinal degenerations based on scientific research originating from the EU-funded DRUGSFORD project. The company translates basic research into therapeutic candidates targeting photoreceptor degeneration diseases such as retinitis pigmentosa and achromatopsia.

1 investor

Miromatrix develops fully biologic organs using decellularization and recellularization technology for transplant patients. The company focuses on engineering transplantable kidneys, livers, and liver support devices to address the critical shortage of donor organs.

1 investor

Mirxes develops RNA-based molecular diagnostics for early cancer detection, treatment selection, and multiomics research. Its offerings span cancer screening blood tests, next-generation sequencing panels, and bioinformatics services for clinical and research partners.

1 investor

Misala adapts, validates, manufactures, and distributes on-patent diagnostics, devices, and therapeutics from universities and research labs for African women's health contexts, using a staged "Reset, Detect, Treat" framework. It serves women and clinicians, starting with a consumer wellness and education arm before expanding into diagnostics and therapeutics adapted for African populations and healthcare systems.

1 investor

MISO Chip develops microfluidic systems and diagnostic technologies for oncology, drug development, and precision medicine applications. The company serves biologists, physicians, and clinical researchers seeking to accelerate the translation of biomedical discoveries into patient treatments.

1 investor

Missouri Innovation Center (MIC) is a company-building platform that provides wet labs, coworking and office space, early-stage capital, operating support, and access to the University of Missouri (Mizzou) network for science and technology founders. Based in Columbia, Missouri, it supports startups in agtech, healthcare, life sciences, and deep tech from first experiment through fundable venture.

1 investor

MIT Life Sciences Angels is an angel investment group affiliated with MIT that focuses on funding life sciences and biotechnology startups, led by experienced entrepreneurs and venture investors.

1 investor

Mitotherapeutix develops siRNA-based drugs using RNA silencing to target disease-related genes, with an initial focus on a protein that regulates mitochondrial metabolic activity. The company aims to create therapies that treat a range of diseases by controlling this metabolic regulator.

1 investor

Mitrix Bio develops bioreactor-grown young mitochondria encased in extracellular vesicles ("Mitlets") intended for transplantation to supplement aging cells. The company targets mitochondrial dysfunction implicated in age-related diseases such as Alzheimer's, retinal disease, liver dysfunction, and immune senescence.

1 investor

MLA Diagnostics develops a melanoma diagnostic test based on DNA methylation biomarkers to improve patient risk stratification and treatment decisions. The company serves oncology practices and pathology labs in the cancer diagnostics market.

1 investor

MNDL Bio combines scientific expertise with product engineering and commercial capabilities to bridge academic biotechnology discoveries and industrial-scale protein production applications.

1 investor